Myriad Genetics, Inc. (MYGN) Tops Q4 EPS by 1c; Guides FY12
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q4 EPS of $0.30, $0.01 better than the analyst estimate of $0.29. Revenue for the quarter came in at $107.4 million versus the consensus estimate of $104.43 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.20-$1.25, versus the consensus of $1.25. Myriad Genetics, Inc. sees FY2012 revenue of $445-$465 million, versus the consensus of $450.8 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.20-$1.25, versus the consensus of $1.25. Myriad Genetics, Inc. sees FY2012 revenue of $445-$465 million, versus the consensus of $450.8 million.